106 related articles for article (PubMed ID: 25119006)
1. Selected morphologic features influencing the prognosis of conventional renal cell carcinomas co-expressing P53 and MDM2.
Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Szopiński T; Chłosta P; Okoń K
Pol J Pathol; 2014 Mar; 65(1):29-33. PubMed ID: 25119006
[TBL] [Abstract][Full Text] [Related]
2. Selected immunohistochemical features of conventional renal cell carcinomas coexpressing P53 and MDM2.
Hejnold M; Dyduch G; Białas M; Demczuk S; Ryś J; Chłosta P; Szopiński T; Okoń K
Pol J Pathol; 2014 Jun; 65(2):113-9. PubMed ID: 25119170
[TBL] [Abstract][Full Text] [Related]
3. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
4. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Suster D; Ronen S; Peterson JF; Mackinnon AC; Hes O; Suster S; Lin DI
Hum Pathol; 2019 May; 87():28-36. PubMed ID: 30825458
[TBL] [Abstract][Full Text] [Related]
6. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
7. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
[TBL] [Abstract][Full Text] [Related]
8. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
12. p53 expression and relationship with MDM2 amplification in breast carcinomas.
Buyukpinarbasili N; Gucin Z; Ersoy YE; İlbak A; Kadioglu H; Muslumanoglu M
Ann Diagn Pathol; 2016 Apr; 21():29-34. PubMed ID: 27040927
[TBL] [Abstract][Full Text] [Related]
13. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
15. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
[TBL] [Abstract][Full Text] [Related]
16. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
19. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma.
Kanamaru H; Li B; Miwa Y; Akino H; Okada K
Urol Res; 1999 Jun; 27(3):169-73. PubMed ID: 10422817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
